The use of and response to second-line protease inhibitor regimens: Results from the EuroSIDA study

AIDS

Volumn 15, Issue 2, 2001, Pages 201-209

  Mocroft, A ^a   Phillips, A N ^a   Miller, V ^a   Gatell, J ^a   Van Lunzen, J ^a   Parkin, J M ^a   Weber, R ^a   Roge, B ^a   Lazzarin, A ^a   Lundgren, J D ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

CD4 lymphocyte count; Clinic cohort; Protease inhibitors; Viral load

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS INHIBITION; VIRUS LOAD;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MALE; NELFINAVIR; PROSPECTIVE STUDIES; RITONAVIR; SAQUINAVIR; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0035951502     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200101260-00009     Document Type: Article

References (29)

1. Changing patterns of mortality across Europe in patients infected with HIV
2. Declining morbidity and mortality among patients with advanced human immunodeficlency virus infection
3. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study
4. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor
5. Predictors of virological success and ensuing failure among HIV+ patients starting HAART in Europe: Results from the EuroSIDA study
6. Natural history of HIV infection in the era of combination antiretroviral therapy
7. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
8. Human immunodeficiency virus 1 protease inhibitors in clinical practise
9. Virological response to protease inhibitor therapy in an HIV clinic cohort
10. Virological failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
11. Antiretroviral therapy in adults: Updated recommendations of the International AIDS society - USA panel
12. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
13. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor containing regimens
14. Activity of a ritonavir plus sacluinavir-containing regimen in patients with virological evidence of indinavir or ritonavir failure
15. The antiviral effect of ritonavir and saquinavir in combination among HIV-infected adults: Results from a community based study
16. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type-1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virological outcome
17. Salvage therapy with regimens containing ritonavir and saquinavir in extensively pretreated HIV-infected patients
18. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: Phenotypic resistance to protease inhibitors predicts outcome of therapy
19. Virological responses to a ritonavir-saquinavir containing regimen in patients who had previously failed nelfinavir
20. Regional differences in use of antiretrovlral agents and primary prophylaxis in 3122 European HIV-infected patients
21. 1993 Revised classification system for HIV infection and expanded case definition for AIDS among adolescents and adults
22. Antiretroviral therapy: Where are we?
23. British HIV association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy
24. Saquinavir soft-gel capsule formulation: A review of its use in patients with HIV infection
25. HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy
26. HIV-1 protease inhibitors. A review for clinicians
27. HIV-protease inhibitors
28. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients
29. EuroSIDA: Temporal changes in the response to HAART